170 related articles for article (PubMed ID: 21715318)
21. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
[TBL] [Abstract][Full Text] [Related]
22. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
[TBL] [Abstract][Full Text] [Related]
23. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Gökbuget N; Stanze D; Beck J; Diedrich H; Horst HA; Hüttmann A; Kobbe G; Kreuzer KA; Leimer L; Reichle A; Schaich M; Schwartz S; Serve H; Starck M; Stelljes M; Stuhlmann R; Viardot A; Wendelin K; Freund M; Hoelzer D;
Blood; 2012 Sep; 120(10):2032-41. PubMed ID: 22493293
[TBL] [Abstract][Full Text] [Related]
24. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
[No Abstract] [Full Text] [Related]
25. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
[TBL] [Abstract][Full Text] [Related]
27. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R
Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
29. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
[TBL] [Abstract][Full Text] [Related]
30. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
31. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
Dhédin N; Huynh A; Maury S; Tabrizi R; Beldjord K; Asnafi V; Thomas X; Chevallier P; Nguyen S; Coiteux V; Bourhis JH; Hichri Y; Escoffre-Barbe M; Reman O; Graux C; Chalandon Y; Blaise D; Schanz U; Lhéritier V; Cahn JY; Dombret H; Ifrah N;
Blood; 2015 Apr; 125(16):2486-96; quiz 2586. PubMed ID: 25587040
[TBL] [Abstract][Full Text] [Related]
32. HiJAKing T-ALL.
Asnafi V
Blood; 2014 Nov; 124(20):3038-40. PubMed ID: 25395141
[TBL] [Abstract][Full Text] [Related]
33. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
[TBL] [Abstract][Full Text] [Related]
34. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
35. T-cell acute lymphoblastic leukemia.
Raetz EA; Teachey DT
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):580-588. PubMed ID: 27913532
[TBL] [Abstract][Full Text] [Related]
36. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
37. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
38. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
39. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.
Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Amini RM; Hallböök H;
Eur J Haematol; 2014; 92(5):377-81. PubMed ID: 24443846
[TBL] [Abstract][Full Text] [Related]
40. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
